Association of molecular markers with clinicopathological factors in breast cancer

Authors

  • Monica Hernández-Frómeta Universidad de Ciencias Médicas de Pinar Del Río. Facultad de Ciencias Médicas Dr Ernesto Che Guevara de la Serna. Pinar Del Río, Cuba. https://orcid.org/0000-0003-3700-5318
  • Yarelis de Armas-Hernández Universidad de Ciencias Médicas de Pinar Del Río. Facultad de Ciencias Médicas Dr Ernesto Che Guevara de la Serna. Pinar Del Río, Cuba. https://orcid.org/0000-0002-5699-314X
  • José Caridad Díaz-Cabrera Universidad de Ciencias Médicas de Pinar Del Río. Facultad de Ciencias Médicas Dr Ernesto Che Guevara de la Serna. Pinar Del Río, Cuba. https://orcid.org/0000-0003-2787-7446
  • Isvel Zaldívar-Garit Universidad de Ciencias Médicas de Pinar Del Río. Facultad de Ciencias Médicas Dr Ernesto Che Guevara de la Serna. Pinar Del Río, Cuba. https://orcid.org/0000-0002-9199-501X

Keywords:

BIOMARKERS, TUMOR, BREAST NEOPLASMS, RECEPTORS.

Abstract

Introduction: the use of biomarkers in breast cancer has made it possible to personalise treatment and prognosis.

Objective: to identify the association between molecular markers and clinicopathological factors in breast cancer in Pinar del Río.

Methods: An observational, descriptive, longitudinal and retrospective probabilistic study was carried out on 384 patients, of which 96 patients with breast cancer diagnosed between January 2007 and December 2011, attended at the Third Congress Oncology Patient Care Centre, were selected. Clinical, anatomopathological, biomolecular and follow-up variables were studied.

Results: The estrogen receptor subtype predominated with 70,8 % followed by progesterone receptors with 56,3 %. Of the women, 34,4 % were in the 51-60 age group. Associations were found between recurrence and estrogen receptor (p=0,03), progestagen receptor (p=0,01) and HER-2 (p=0,02) subtypes; the latter two also showed association with metastasis, with an OR=23,92 for HER-2 positive.

Conclusions: no association was found between the clinical characteristics studied and the molecular subtypes. Tumours with HER-2 expression tended to have a greater dispersion of their diameters. Recurrence was associated with all subtypes, while metastasis was associated with progesterone receptor-positive and HER-2-positive subtypes, the latter increasing the risk of metastasis.

Downloads

Download data is not yet available.

Author Biography

Monica Hernández-Frómeta, Universidad de Ciencias Médicas de Pinar Del Río. Facultad de Ciencias Médicas Dr Ernesto Che Guevara de la Serna. Pinar Del Río, Cuba.

Ciencias basicas biomedicas

References

1. Santiago Pérez JT, Rivera Valdespino A de la C, Gil Valdés D. Carcinoma de mama masculina. Revista Cubana de Cirugía [Internet]. marzo de 2018 [citado 23/06/2021]; 57(1):78-86. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0034-74932018000100010&lng=es&nrm=iso&tlng=es

2. Reina Suárez M, Ramos Rangel Y, Cisnero Pimentel L, Reina Sarmiento M, Alcelú Sarduy M, González Suárez M. Caracterización de pacientes con cáncer de mama y sus familiares acompañantes. MediSur [Internet]. febrero de 2018 [citado 23/06/2021]; 16(1):47-54. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1727-897X2018000100008&lng=es&nrm=iso&tlng=es

3. Goyanes R, Escobar-Pérez X, Camacho R, López M, Odio S, Llanes-Fernández L, et al. Receptores Hormonales y otros Factores Pronósticos en Cáncer de mama en Cuba. Revista del Instituto Nacional de Cancerología [Internet]. 2008 [citado 23/06/2021];3: 19-27. Disponible en:

https://www.researchgate.net/publication/266852955

4. Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. El cáncer de mama en el siglo XXI: de la detección precoz a los nuevos tratamientos. Radiologia [Internet]. 1 de septiembre de 2017 [citado 23/06/2021]; 59(5):368-79. Disponible en: https://www.elsevier.es/es-revista-radiologia-119-articulo-el-cancer-mama-el-siglo-S0033833817301017

5. MINSAP. Anuario Estadístico. 2017. Mortalidad por tumores malignos en el sexo femenino según localización y grupo de edad. La Habana: Ministerio de Salud Pública; 2017.

6. MINSAP. Anuario Estadístico. 2018. Mortalidad por tumores malignos en el sexo femenino según localización y grupo de edad. La Habana: Ministerio de Salud Pública; 2018.

7. Osorio Bazar N, Bello Hernández C, Vega Bazar L. Factores de riesgo asociados al cáncer de mama. Rev Cubana Med Gen Integr [Internet]. 2020 Jun [citado 09/08/2020]; 36(2): e1147. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252020000200009&lng=es

8. Coughlin SS. Epidemiology of Breast Cancer in Women. AdvExp Med Biol [Internet]. 2019 [citado 09/08/2020]; 1152: 9-29. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31456177/

9. Banin Hirata BK, Oda JMM, Losi Guembarovski R, Ariza CB, Oliveira CEC de, Watanabe MAE. Molecular Markers for Breast Cancer: Prediction on Tumor Behavior. Disease Markers [Internet]. 28 de enero de 2014 [citado 23/06/2021]; 2014:e513158. Disponible en: https://www.hindawi.com/journals/dm/2014/513158/

10. Ventura AC, Merajver SD. Genetic Determinants of Aggressive Breast Cancer. Annu Rev Med [Internet]. 1 de febrero de 2008 [citado 23/06/2021]; 59(1):199-212. Disponible en: https://www.annualreviews.org/doi/10.1146/annurev.med.59.060106.184830

11. Rivera Ledesma E, Fornaris Hernández A, Mariño Membribes ER, Alfonso Díaz K, Ledesma Santiago RM, Abreu Carter IC, et al. Factores de riesgo del cáncer de mama en un consultorio de la Atención Primaria de Salud. Revista Habanera de Ciencias Médicas [Internet]. abril de 2019 [citado 23/06/2021]; 18(2): 308-22. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1729-519X2019000200308&lng=es&nrm=iso&tlng=es

12. Cathcart-Rake EJ, Ruddy KJ, Johnson RH. Modifiable Risk Factors for the Development of Breast Cancer in Young Women. Cancer J [Internet]. diciembre de 2018 [citado 23/06/2021]; 24(6): 275-284. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30480572/

13. Khurshid Z, Zafar MS, Khan RS, Najeeb S, Slowey PD, Rehman IU. Chapter Two - Role of Salivary Biomarkers in Oral Cancer Detection. En: Makowski GS, editor. Advances in ClinicalChemistry [Internet]. Elsevier; 2018 [citado 23/06/2021]: 23-70. Disponible en: https://shop.elsevier.com/books/advances-in-clinical-chemistry/makowski/978-0-12-803314-2

14. Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. TrastuzumabEmtansine for Residual Invasive HER2-Positive Breast Cancer New England Journal of Medicine [Internet]. 2019 [citado 23/06/2021]; 380(7): 617-28. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30516102/

Downloads

Published

2023-08-04

How to Cite

1.
Hernández-Frómeta M, de Armas-Hernández Y, Díaz-Cabrera JC, Zaldívar-Garit I. Association of molecular markers with clinicopathological factors in breast cancer. Rev Ciencias Médicas [Internet]. 2023 Aug. 4 [cited 2025 Sep. 17];27:e5882. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/5882

Issue

Vol. 27 (2023): (Sistema de Publicación Continua)

Section

ORIGINAL ARTICLES

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/